What do systematic reviews say?

Biological therapy vs placebo, best supportive care (BSC) or no treatment

Biological therapy showed no clear difference in any adverse events compared with placebo, best supportive care (BSC) or no treatment (high certainty).

• Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
  RR 1.08 [1, 1.17]
  1 study · 491 participants
  High

Biological therapy vs placebo, best supportive care (BSC) or no treatment

• Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 283 participants
  Low

Biological therapy vs placebo, best supportive care (BSC) or no treatment

Biological therapy leads to lower overall survival compared with placebo, best supportive care (BSC) or no treatment (high certainty).

• Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
  HR 0.55 [0.41, 0.73]
  3 studies · 781 participants
  High

Biological therapy vs placebo, best supportive care (BSC) or no treatment

Biological therapy probably leads to lower progression‐free survival compared with placebo, best supportive care (BSC) or no treatment (moderate certainty).

• Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
  HR 0.33 [0.19, 0.57]
  3 studies · 781 participants
  Moderate

Biological therapy vs placebo, best supportive care (BSC) or no treatment

Biological therapy showed no clear difference in serious adverse events compared with placebo, best supportive care (BSC) or no treatment (low certainty).

• Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
  RR 1.14 [0.95, 1.37]
  2 studies · 638 participants
  Low

Biological therapy vs placebo, best supportive care (BSC) or no treatment

Biological therapy may leads to higher tumour response rate compared with placebo, best supportive care (BSC) or no treatment (low certainty).

• Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
  RR 5.12 [1.23, 21.27]
  3 studies · 687 participants
  Low

Chemmotherapy combined with biological therapy vs chemotherapy alone

Chemmotherapy combined with biological therapy showed no clear difference in overall survival compared with chemotherapy (moderate certainty).

• Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
  HR 0.93 [0.83, 1.04]
  7 studies · 2743 participants
  Moderate

Chemmotherapy combined with biological therapy vs chemotherapy alone

It is very uncertain whether chemmotherapy combined with biological therapy changes progression‐free survival compared with chemotherapy (very low certainty).

• Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
  HR 0.87 [0.74, 1.02]
  7 studies · 2743 participants
  Very low

Chemmotherapy combined with biological therapy vs chemotherapy alone

It is very uncertain whether chemmotherapy combined with biological therapy changes serious adverse events compared with chemotherapy (very low certainty).

• Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
  RR 1.17 [0.95, 1.44]
  4 studies · 1618 participants
  Very low

Chemmotherapy combined with biological therapy vs chemotherapy alone

It is very uncertain whether chemmotherapy combined with biological therapy changes tumour response rate compared with chemotherapy (very low certainty).

• Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
  RR 1.35 [0.99, 1.85]
  6 studies · 2404 participants
  Very low

Chemmotherapy combined with biological therapy vs chemotherapy alone

Chemmotherapy combined with biological therapy showed no clear difference in any adverse events compared with chemotherapy (moderate certainty).

• Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
  RR 1.01 [1, 1.03]
  3 studies · 1513 participants
  Moderate

Chemmotherapy combined with biological therapy vs chemotherapy alone

Chemmotherapy combined with biological therapy showed no clear difference in quality of life (QoL) compared with chemotherapy (low certainty).

• Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
  HR 0.88 [0.74, 1.04]
  2 studies · 1154 participants
  Low